Drug Trial Radar · NCT03903939
Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure
Last checked: Nov 20, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
May 22, 2019
Primary completion
Nov 14, 2021
Study completion Nov 14, 2021
Sponsor
- Lead sponsor
- Pär JohanssonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Odense University Hospital; Aarhus University Hospital; Aalborg University Hospital; Oslo University Hospital
- First posted
- Apr 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized (1:1, iloprost: placebo), placebo controlled, blinded, investigator-initiated phase 2b trial in trauma patients with haemorrhagic shock and shock induced endotheliopathy (SHINE), investigating the efficacy and safety of continuous intravenous administrating of iloprost (1 ng/kg/min) versus placebo for 72-hours, in a total of 220 patients. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in trauma patients with haemorrhagic shock (SHINE) suffering from organ failure caused by endothelial breakdown, ultimately improving survival.
Conditions
- Multi Organ Failure
Interventions
IloprostDrug
continuously infusion for 72 hours 1 ng/kg/min
Isotonic salineDrug
continuously infusion for 72 hours equal volume to Iloprost
Primary outcomes
What the sponsor says the trial is designed to measure.
- ICU free daysTime frame: 28 days after admission
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet (University of Copenhagen)
Copenhagen, Denmark
Odense University Hospital
Odense, Denmark
Oslo University Hospital
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.